Quick Answer
Xilio Therapeutics, Inc. reported Net Income of -$35.04 million for fiscal year 2025.
Xilio Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$35.04M | +39.8% |
| 2024 | -$58.24M | +23.8% |
| 2023 | -$76.40M | +13.4% |
| 2022 | -$88.22M | -16.4% |
| 2021 | -$75.80M | -37.3% |
| 2020 | -$55.22M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$16.29M | -16.2% | -2.8% |
| June 30, 2025 | -$15.84M | -13.8% | -19.4% |
| March 31, 2025 | -$13.27M | +22.9% | +5.4% |
| September 30, 2024 | -$14.02M | +16.3% | -0.7% |
| June 30, 2024 | -$13.93M | +28.1% | +19.1% |
| March 31, 2024 | -$17.20M | +24.0% | -2.7% |
| September 30, 2023 | -$16.75M | +15.4% | +13.5% |
| June 30, 2023 | -$19.36M | +21.4% | +14.5% |
- Xilio Therapeutics, Inc. showed an increase of +39.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, Xilio Therapeutics, Inc.’s net income has grown by 36.6% (from -$55.22 million to -$35.04 million).
- The most recent figure is from Xilio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: